
STATEMENT OF PURPOSE

RS27259 / H0315

The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled Substances Act. If any substance is designated, rescheduled, or deleted as a controlled substance under federal law and notice thereof is given to the Board, the Board shall similarly control the substance unless the Board objects to the inclusion, rescheduling, or deletion. This bill mirrors DEA scheduling decisions for 2019, including placing synthetic cannabinoids, synthetic cathinones, and synthetic fentanyls in Schedule I.

FISCAL NOTE

This legislation will have no fiscal impact to the General Fund or the Board of Pharmacy's dedicated fund. It has no fiscal impact because adding, removing, or rescheduling products to the Controlled Substances Act does not create any new state program and does not compel any state action.



DISCLAIMER: This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative process, including judicial review (Joint Rule 18).